Provided is a novel fluorescent probe which can be used in a spray manner, has an outstandingly high sensitivity-specificity with instantaneousness, and enables detection of a brain tumor.

A fluorescent probe for detecting a brain tumor, including a compound of the following formula (I) or a salt thereof:

##STR00001##

wherein P1 represents an arginine residue, a histidine residue or a tyrosine residue, P2 represents a proline residue or a glycine residue, where P1 is linked to an adjacent N atom by forming an amide bond, and P2 is linked to P1 by forming an amide bond; R.sup.1 represents a hydrogen atom, or 1 to 4 identical or different substituents each independently selected from the group consisting of an optionally substituted alkyl group, a carboxyl group, an ester group, an alkoxy group, an amide group and an azide group; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently represent a hydrogen atom, a hydroxyl group, an optionally substituted alkyl group or a halogen atom; R.sup.8 and R.sup.9 each independently represent a hydrogen atom or an alkyl group;

X represents O, Si(R.sup.a)(R.sup.b), Ge(R.sup.a)(R.sup.b), Sn(R.sup.a)(R.sup.b), C(R.sup.a) (R.sup.b) or P(═O)(R.sup.a); R.sup.a and R.sup.b each independently represent a hydrogen atom, an alkyl group or an aryl group; and Y represents a C.sub.1-C.sub.3 alkylene group.

The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.

The present disclosure is directed to conjugates of a specific binding entity and an oligomer, i.e. [Specific Binding Entity]-[Oligomer].sub.n, wherein n is an integer ranging from 1 to 12, and where the Oligomer includes, in some embodiments, a PNA sequence having at least one substituent at a gamma carbon position. In some embodiments, the substituent at the gamma carbon position, e.g. an amino acid, a peptide, a miniPEG, or a polymer, includes at least one reporter moiety.

Embodiments related to medical imaging devices including rigid imaging tips and their methods of use for identifying abnormal tissue within a surgical bed are disclosed.

The present disclosure provides a method of detecting a joint disease, the method comprising administering a composition comprising an agent chosen from LS301, LS838, or a derivative thereof to a subject in need thereof; and detecting a signal intensity emitted from the agent in at least one joint of the subject, wherein detection of signal intensity above a baseline value indicates the subject has the joint disease. Also are provided are methods for monitoring the progression of a joint disease, monitoring treatment response to a therapeutic agent for treating a joint disease, and treating a joint disease.

The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.

The disclosure is directed to conjugates, e.g. PNA conjugates, as well as methods of employing the conjugates for detecting one or more targets in a biological sample, e.g. a tissue sample.

The present invention describes a composition comprising a fluorophore labelled uPAR-targeting component, a buffer and a surfactant, wherein the fluorophore labelled uPAR-targeting component is solubilized in the composition by means of the surfactant being present, and wherein the composition comprises a maximum of 10 wt % water, preferably a maximum of 5 wt % water.

Provided is a modified J-aggregate (MJ). In some embodiments, the MJ is nanoscale, sub-micronscale, or microscale. Also provided is an MJ conjugate. Also provided are processes for making an MJ or an MJ conjugate. Photoacoustic imaging methods employing the MJ or MJ conjugate are also provided.

In one aspect, the present disclosure relates to a masked fluorogenic compound comprising a small molecule protecting group that can be cleaved following a reaction with a biomarker. In some embodiments, cleavage of the small molecule protecting group provides a fluorogenic ligand that binds to an aptamer, leading to fluorescence emission. In another aspect, the present disclosure relates to a method of detecting a disease or a disorder in a subject and/or in a biological sample from the subject.